Disposition of 18931 shares by Shah Preetam of Cidara Therapeutics at 0.6698 subject to Rule 16b-3
| CDTX Stock | USD 24.90 1.05 4.40% |
Slightly above 54% of Cidara Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Cidara Therapeutics suggests that some traders are interested. Cidara Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Cidara Therapeutics' earnings reports, geopolitical events, and overall market trends.
Cidara |
Filed transaction by Cidara Therapeutics Officer: Cfo & Cbo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cidara Therapeutics Fundamental Analysis
We analyze Cidara Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cidara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cidara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Cidara Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Cidara Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cidara Therapeutics stock to make a market-neutral strategy. Peer analysis of Cidara Therapeutics could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics with similar companies.
Peers
Cidara Therapeutics Related Equities
| GLYC | GlycoMimetics | 3.85 | ||||
| CTMX | CytomX Therapeutics | 1.45 | ||||
| CLSD | Clearside Biomedical | 3.37 |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.